IP Library Granted Patent US 7,659,097
Granted Patent B2
US 7,659,097 · App. 11/754,235 · Granted Feb 9, 2010

Production of isoprenoids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,659,097
App. No.
11/754,235
Granted
Feb 9, 2010
Kind
B2
Abstract

The present invention provides methods for a robust production of isoprenoids via one or more biosynthetic pathways. The invention also provides nucleic acids, enzymes, expression vectors, and genetically modified host cells for carrying out the subject methods. The invention also provides fermentation methods for high productivity of isoprenoids from genetically modified host cells.

Claims (43)

1. A method for producing an isoprenoid comprising:

(a) obtaining a plurality of bacterial or fungal host cells that comprise a heterologous nucleic acid encoding one or more enzymes of a mevalonate pathway for making isopentenyl pyrophosphate, wherein expression of the one or more enzymes is under control of at least one heterologous transcriptional regulator, wherein said mevalonate pathway comprises (i) an enzyme that condenses acetoacetyl-CoA with acetyl-CoA to form HMG-CoA; (ii) an enzyme that converts HMG-CoA to mevalonate; (iii) an enzyme that phosphorylates mevalonate to mevalonate 5-phosphate; (iv) an enzyme that converts mevalonate 5-phosphate to mevalonate 5-pyrophosphate; and (v) an enzyme that converts mevalonate 5-pyrophosphate to isopentenyl pyrophosphate; and

(b) culturing the bacterial or fungal host cells in a medium in which carbon source is limited so that the medium provides for about 75% or less of maximum specific growth rate for the bacterial or fungal host cells, wherein said maximum specific growth rate is a rate that would have been achieved by culturing the bacterial or fungal host cells under optimal temperature for growth of the bacterial or fungal host cells, and in a medium in which nutrients are present in excess.

2. The method of claim 1 wherein the at least one heterologous transcriptional regulator is inducible.

3. The method of claim 1 wherein the mevalonate pathway enzymes are under control of a single transcriptional regulator.

4. The method of claim 1 wherein the mevalonate pathway enzymes are under control of a multiple transcriptional regulator.

5. The method of claim 1 wherein the host cells comprise a plurality of heterologous nucleic acids encoding all of the enzymes of a mevalonate pathway.

6. The method of claim 1 wherein the bacterial cells are E coli.

7. The method of claim 1 wherein the heterologous nuckic acid comprises a nucleic acid sequence encoding a mevaloante pathway enzyme from a fungus having an endogenous mevalonate pathway.

8. The method of claim 1 wherein the host cells are S. cerevisiae.

9. The method of claim 1 wherein the heterologous nucleic acid comprises a nucleic acid sequence encoding a mevalonate pathway enzyme from a bacterium having an endogenous mevalonate pathway.

10. The method of claim 9 wherein the bacterium is of the genus selected from Enterococcus, Pseudomonas , and Staphyloccoccus.

11. The method of claim 1 wherein the heterologous nucleic acid comprises a nucleic acid sequence encoding a mevaloante pathway enzyme selected from acetyl-CoA thiolase, HMG-CoA synthase, HMG-CoA reductase, and mevalonate kinase.

12. The method of claim 1 wherein the heterologous nucleic acid comprises a nucleic acid sequence encoding a Class II HMG reductase.

13. The method of claim 1 wherein the host cells are cultured in the medium wherein nutrient and temperature both are maintained at a level below that which would provide for the maximum specific growth rate for the host cells.

14. The method of claim 1 wherein the temperature of the medium is at least 2-20° C. below the optimal temperature.

15. The method of claim 14 wherein the host cells are cultured at a temperature at least 5° C. below the optimal temperature.

16. The method of claim 14 wherein the temperature of the medium is at least 10° C. below the optimal temperature.

17. The method of claim 1 wherein the medium will provide for about 60% or less of the maximum specific growth rate.

18. The method of claim 1 wherein the medium will provide for about 50% or less of the maximum specific growth rate.

19. The method of claim 1 wherein the medium will provide for about 40% or less of the maximum specific growth rate.

20. The method of claim 1 wherein the medium will provide for about 25% or less of the maximum specific growth rate.

21. The method of claim 1 wherein the medium will provide for about 75%-10% of the maximum specific growth rate.

22. The method of claim 1 wherein the medium is nitrogen-restricted.

23. The method of claim 1 wherein the isoprenoid is produced in an amount greater than about 10 grams per liter of medium.

24. The method of claim 1 wherein the isoprenoid is produced in an amount greater than about 50 mg per gram of dry cell weight.

25. The method of any one of claims 23 or 24 wherein the amount of isoprenoid is produced in less tan about 150 hours.

26. The method of claim 23 or 24 wherein the amount of isoprenoid is produced in less than about 96 hours.

27. The method of claim 23 or 24 wherein the amount of isoprenoid is produced in less than about 72 hours.

28. The method of claim 1 wherein the isoprenoid is selected from the group consisting of a hemiterpene, monoterpene, diterpene, triterpene, tetraterpene, sesquiterpene, and polyterpene.

29. The method of claim 1 wherein the isoprenoid is a sesquiterpene.

30. The method of claim 1 wherein the isoprenoid is a C 5 -C 20 isoprenoid.

31. The method of claim 1 wherein the isoprenoid is selected from the group consisting of abietadiene, amorphadiene, carene, α-famesene, β-farnesene, farnesol, geraniol, geranylgeraniol, isoprene, linalool, limonene, myrcene, nerolidol, ocimene, patchoulol, β-pinene, sabinene, γ-terpinene, terpindene and valencene.

32. The method of claim 1 , wherein the nutrients comprise carbon source and nitrogen source.

33. The method of claim 29 wherein the sescjuiterpene is α-farnesene.

34. The method of claim 29 wherein the sesquiterpene is β-farnesene.

35. The method of claim 29 wherein the sesquiterpene is amorphadiene.

36. The method of claim 29 wherein the sesquiterpene is farnesol.

37. The method of claim 29 wherein the sesquiterpene is nerolidol.

38. The method of claim 30 wherein the sesquiterpene is patchoulol.

39. The method of claim 30 wherein the sesquiterpene is valencene.

40. The method of claim 1 , wherein said one or more enzymes is a bacterial enzyme.

41. The method of claim 1 , wherein said one or more enzymes is a fbngal enzyme.

Assignments (21)
SECURITY INTEREST Recorded May 24, 2024
From: AMYRIS, INC.
To: EUAGORE, LLC
Reel/Frame 067528/0467 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2024
From: LAVVAN, INC.
To: AMYRIS, INC.
Reel/Frame 066953/0375 →
SECURITY INTEREST Recorded Aug 17, 2023
From: AMYRIS, INC.; AMYRIS CLEAN BEAUTY, INC.; AMYRIS FUELS, LLC; AB TECHNOLOGIES LLC; APRINNOVA, LLC; AMYRIS-OLINKA, LLC; ONDA BEAUTY INC.; UPLAND 1 LLC; AMYRIS ECO-FAB LLC; CLEAN BEAUTY 4U HOLDINGS, LLC; AMYRIS CLEAN BEAUTY LATAM LTDA; INTERFACES INDUSTRIA E COMERCIA DE COSMETICOS LTDA; AMYRIS BIOTECHNOLOGIA DO BRASIL LTDA; AMYRIS EUROPE TRADING B.V. (NETHERLANDS); AMYRIS BIO PRODCUTS PORTUGAL, UNIPESSOAL, LDA; BEAUTY LABS INTERNATIONAL LIMITED; AMYRIS UK TRADING LIMITED
To: EUAGORE, LLC
Reel/Frame 064619/0778 →
SECURITY INTEREST Recorded Aug 3, 2023
From: AMYRIS CLEAN BEAUTY, INC.; AMYRIS FUELS, LLC; AB TECHNOLOGIES LLC; AMYRIS, INC.
To: MUIRISC, LLC
Reel/Frame 064492/0518 →
RELEASE OF SECURITY INTEREST Recorded Feb 14, 2023
From: SCHOTTENFELD OPPORTUNITIES FUND II, L.P.
To: AMYRIS, INC.
Reel/Frame 062760/0818 →
RELEASE OF SECURITY INTEREST Recorded Feb 14, 2023
From: NAXYRIS S.A.
To: AMYRIS, INC.
Reel/Frame 062760/0753 →
SECURITY INTEREST Recorded Oct 18, 2022
From: AMYRIS, INC.
To: FORIS VENTURES, LLC
Reel/Frame 061703/0499 →
GRANT OF PATENT SECURITY INTEREST Recorded Nov 20, 2019
From: AMYRIS, INC.
To: SCHOTTENFELD OPPORTUNITIES FUND II, L.P.
Reel/Frame 051072/0310 →
RELEASE OF SECURITY INTEREST Recorded Aug 28, 2019
From: STEGODON CORPORATION
To: AMYRIS, INC.
Reel/Frame 050206/0606 →
SECURITY INTEREST Recorded Aug 16, 2019
From: AMYRIS, INC.
To: NAXYRIS S.A.
Reel/Frame 050081/0106 →
CHANGE OF NAME Recorded Nov 17, 2017
From: AMYRIS BIOTECHNOLOGIES
To: AMYRIS, INC.
Reel/Frame 044483/0245 →
SECURITY INTEREST Recorded Jun 16, 2016
From: HERCULES CAPITAL INC.
To: STEGODON CORPORATION
Reel/Frame 039048/0251 →
SECURITY INTEREST Recorded Jun 3, 2016
From: AMYRIS, INC.
To: HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
Reel/Frame 038878/0381 →
RELEASE OF SECURITY INTEREST Recorded Mar 31, 2014
From: MAXWELL (MAURITIUS) PTE LTD
To: AMYRIS, INC.
Reel/Frame 032578/0357 →
RELEASE OF SECURITY INTEREST Recorded Mar 28, 2014
From: TOTAL ENERGIES NOUVELLES ACTIVITES USA, SAS (F/K/A TOTAL GAS & POWER USA, SAS)
To: AMYRIS, INC.
Reel/Frame 032554/0001 →
RELEASE OF SECURITY INTEREST Recorded Mar 27, 2014
From: TOTAL ENERGIES NOUVELLES ACTIVITIES USA, SAS (F/K/A TOTAL GAS & POWER USA, SAS)
To: AMYRIS, INC.
Reel/Frame 032551/0828 →
SECURITY AGREEMENT Recorded Nov 8, 2013
From: AMYRIS, INC.
To: TOTAL ENERGIES NOUVELLES ACTIVITES USA
Reel/Frame 031607/0314 →
SECURITY AGREEMENT Recorded Oct 23, 2013
From: AMYRIS, INC.
To: MAXWELL (MAURITIUS) PTE LTD
Reel/Frame 031478/0933 →
SECURITY AGREEMENT Recorded May 8, 2013
From: AMYRIS, INC.
To: TOTAL GAS & POWER USA, SAS
Reel/Frame 030378/0447 →
CHANGE OF NAME Recorded Jul 12, 2011
From: AMYRIS BIOTECHNOLOGIES, INC.
To: AMYRIS, INC.
Reel/Frame 026578/0388 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2008
From: RENNINGER, NEIL STEPHEN; NEWMAN, JACK; REILING, KEITH KINKEAD; REGENTIN, RIKA; PADDON, CHRISTOPHER JOHN
To: AMYRIS BIOTECHNOLOGIES, INC.
Reel/Frame 021102/0625 →